Clinical Report: CRISPR Gene Editing Shows Phase 3 Success in HAE

Overview

Intellia Therapeutics has reported significant Phase 3 results for its CRISPR gene editing therapy, lonvoguran ziclumeran (lonvo-z), demonstrating an 87% reduction in hereditary angioedema (HAE) attacks compared to placebo. The therapy targets the KLKB1 gene, offering a potential one-time treatment option for patients.

Background

Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling. Current treatment options often require chronic therapy, which may not be effective for all patients. The development of gene editing therapies like lonvo-z represents a promising advancement in addressing the underlying genetic causes of HAE, potentially transforming patient management.

Data Highlights

Key Findings

• Lonvoguran ziclumeran reduced HAE attacks by 87% compared to placebo.
• 62% of patients experienced complete freedom from attacks and ongoing medication.
• Safety profile showed only mild-to-moderate adverse events.
• Intellia has initiated a rolling biologics license application with the FDA.
• Potential market launch in the US is targeted for 2027.

Clinical Implications

The positive Phase 3 results for lonvo-z suggest a significant advancement in the treatment of hereditary angioedema, potentially allowing for a one-time therapeutic intervention. Clinicians should stay informed about the upcoming FDA approval process and consider the implications for patient management strategies.

Conclusion

The success of lonvoguran ziclumeran in Phase 3 trials marks a critical milestone in gene therapy for hereditary angioedema, highlighting the potential of CRISPR technology in treating genetic disorders.

References

1. Intellia Therapeutics, Intellia Therapeutics, 2023 -- Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
2. The 2025 WAO Guidelines for the classification, diagnosis, and treatment of hereditary angioedema, with consideration of worldwide disparities, 2025 -- WAO Guidelines
3. the medicine maker — This Week’s CGT News: New FDA Genome Editing Guidance 
4. the medicine maker — Roving Reporter Asks: What Was the Biggest Development in CGT of 2025?
5. Basic Research in Cardiology — Position Statement from DGK and DZHK on Genome Editing: Applications in Basic Science and Future Outlook
6. the medicine maker — Cirena Launches High-Purity Long RNA to Accelerate CRISPR and Genome-Editing Research
7. The 2025 WAO Guidelines for the classification, diagnosis, and treatment of hereditary angioedema, with consideration of worldwide disparities
8. Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study - PMC
9. Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing - Intellia Therapeutics